Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cerebral Autoregulatory Function Before, During, and After Therapeutic Interventions Following Severe Traumatic Brain Injury: A Secondary Analysis of the BOOST-II Study
Neurocritical Care
S21 - Neurocritical Care (1:00 PM-1:12 PM)
001

BOOST-II used a tier-based management protocol based on brain tissue oxygen (PbtO2) and ICP monitoring to reduce BTH after severe TBI. To explore the underlying pathophysiologic mechanisms, we performed a secondary analysis assessing the relationship between BTH and BP. We hypothesized that BP management below lower limit of autoregulation (LLA) leads to cerebral hypoperfusion and BTH, which can be improved with hemodynamic augmentation.

To investigate the effect of cerebral perfusion pressure (CPP) augmentation on cerebral autoregulatory function and brain tissue hypoxia (BTH).

Of the 106 patients enrolled in BOOST-II, 55 patients had simultaneous recordings of arterial BP, ICP, and PbtO2. Autoregulatory function was measured by interrogating changes in PbtO2 in response to fluctuations in CPP using time-correlation analysis. The resulting autoregulatory index (ORx) identified “optimal” CPP (CPPopt) and limits of autoregulation (LA) for each patient. Autoregulatory function and percent time of CPP outside personalized LA were calculated before, during, and after interventions directed at optimizing CPP.

Individualized LA were computed in 50 patients (age 38.2±18.2, 76% male, monitoring time 92.8±42.4 hours). We identified 35 episodes (in 6 patients) of BTH (PbtO2<20 mmHg) treated with CPP augmentation. Following each intervention, mean CPP increased from 73±14 to 79±19 mmHg (p=0.15), and mean PbtO2 improved from 18.4±5.6 to 21.9±5.6 (p=0.01), while autoregulatory function trended towards improvement (ORx: 0.42 vs. 0.37, p=0.14). Though CPPopt and LA remained relatively unchanged, there was a significant decrease in percent time of CPP below LLA in the 60 minutes after compared to before an intervention (11% vs. 23%, p=0.05).

Our analysis suggests that BTH is associated with cerebral hypoperfusion characterized by an increased time of CPP below LLA. Interventions to increase CPP appear to restore autoregulation, resulting in improved PbtO2. Further studies validating the importance of autoregulation as a modifiable variable, with potential to improve outcomes, are needed.

Authors/Disclosures
Ayush Prasad (Yale School of Medicine & Yale - New Haven Hospital)
PRESENTER
Mr. Prasad has nothing to disclose.
Jessica Kobsa (Yale University) Ms. Kobsa has nothing to disclose.
Alexandria Soto Ms. Soto has nothing to disclose.
David Bartolome (Yale University School of Medicine) Mr. Bartolome has nothing to disclose.
Yelyzaveta Begunova Miss Begunova has nothing to disclose.
Jennifer A. Kim, MD (Yale University School of Medicine) Dr. Kim has nothing to disclose.
Emily J. Gilmore, MD (Yale University School of Medicine) Dr. Gilmore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for carpl.ai. Dr. Gilmore has received personal compensation in the range of $0-$499 for serving as a Consultant for AAN. Dr. Gilmore has received research support from NIH.
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care) Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
Charles Matouk No disclosure on file
Adam De Havenon, MD, FAAN (Yale University) Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has stock in Certus. Dr. De Havenon has stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
Ramon R. Diaz-Arrastia, MD, PhD, FAAN (University of Pennsylvania) Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ischemix, Inc. Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pinteon Therapeutics. Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BrainBox, LLC. Dr. Diaz-Arrastia has received stock or an ownership interest from BrainBox, LLC. Dr. Diaz-Arrastia has received stock or an ownership interest from NovaSignal . Dr. Diaz-Arrastia has received stock or an ownership interest from Nia Therpeutics. The institution of Dr. Diaz-Arrastia has received research support from National Institutes of Health. The institution of Dr. Diaz-Arrastia has received research support from Department of Defense.
Nils Petersen, MD (Yale University) Dr. Petersen has received research support from NIH.